Ionis Pharmaceuticals shared two-year results for DAWNZERA® at ACAAI 2026, showing fewer hereditary angioedema attacks.

IONS · Ionis Pharmaceuticals

The AI's read

This adds evidence that DAWNZERA's effect can last and that patients can keep control of HAE attacks. No new safety signals were reported. The results come from extension and switch groups. The report gives no new approval or sales figures, so the benefit is stronger evidence for the drug, not proof of added sales.